Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2012. The report details a specific share repurchase transaction executed on November 7, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,500,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,414.5 pence per share; lowest price paid was 1,381.5 pence per share.
- Treasury Holdings (Settled): 522,290,427 shares (9.59% of total issued share capital).
- Treasury Holdings (Including Unsettled): 526,940,427 shares (10.70% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,923,148,392 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,500,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.59% of issued capital and 10.70% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (522,290,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,923,148,392 shares in issue) for disclosure threshold assessments.
- Check the settlement status of the 1,500,000 shares purchased on November 7, 2012, to reconcile the difference between settled and unsettled treasury holdings.